FY2022 Q3 Financial and R&D Update

Core Operating Profit Decreased by 4.7 Bn JPY (Decreased by 1.5 Bn JPY excl. forex impact) FY2021 Q3 YTD Results 123.0 Revenue 137.3 Cost of Sales SG&A Expenses R&D Expenses Forex Impact 75.6 FY2022 Q3 YTD 118.3 Results 45.3 Positive Factors 42.4 Revenue +137.3 incl. forex impact of +72.3 Cost of Sales -21.4 Improvement in cost of sales ratio by change in product mix 21.4 SG&A Expenses Negative Factors +42.4 Daiichi-Sankyo (Bn JPY) Increase in expenses related to Enhertu due to an increase in profit share of gross profit with AstraZeneca R&D Expenses +45.3 Increase in 3ADCS* R&D investments Forex Impact +75.6 (Profit Decreased) Cost of Sales +15.6 SG&A Expenses +32.7 R&D Expenses +27.3 * 3ADCs: 1) Enhertu, Trastuzumab deruxtecan (T-DXd, DS-8201), 2) Datopotamab deruxtecan (Dato-DXd, DS-1062) and 3) Patritumab deruxtecan (HER3-DXd, U3-1402) 6

View entire presentation